Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis

Bar-Sela, Gil; Samih, Yousef; Yerushalmi, Rinat; Leviov, Michelle; Ben-Baruch, Noa; Kuchuk, Iryna; Tokar, Margarita; Peretz-Yablonski, T.; Sonnenblick, Amir; Soussan‐Gutman, Lior; Bareket‐Samish, Avital; Fried, Georgeta; Paluch‐Shimon, Shani; Kaufman, Bella; Hammerman, Ariel; Liebermann, Nicky; Stemmer, Salomon M.

doi:10.1111/tbj.13870

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Clalit Health Services (CHS) registry includes all RS data for patients tested through CHS (the largest health maintenance organization in Israel) since 2006. Various analyses of the registry data have been published thus far, including 5-year and 10-year outcome data overall and by ethnicity 9 – 12 .…”

Section: Introductionmentioning

confidence: 99%

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Shachar,

Leviov,

Yerushalmi

et al. 2023

npj Breast Cancer

Self Cite

View full text Add to dashboard Cite

Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a ‘study-cohort’ (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a ‘general 21-gene-tested BC-cohort’ (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the ‘study-cohort’ were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.

show abstract

Section: Introductionmentioning

confidence: 99%

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Shachar,

Leviov,

Yerushalmi

et al. 2023

npj Breast Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…Since the start of the reimbursement of the assay by Clalit Health Services (CHS; the largest health maintenance organization in Israel with approximately 4 million members) in 2006, data on assays performed through CHS were collected in a registry. Various analyses of the registry data have been published thus far, including 5- and 10-year clinical outcome data 10 – 13 .…”

Section: Introductionmentioning

confidence: 99%

Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study

Rotem,

Peretz,

Leviov

et al. 2023

npj Breast Cancer

Self Cite

View full text Add to dashboard Cite

Data on adjuvant chemotherapy (CT) benefit in ER + HER2‒ early-stage breast cancer (EBC) patients with Recurrence Score (RS) 26-30 are limited. This real-world study evaluated the relationships between the RS, adjuvant treatments, and outcomes in 534 RS 26-30 patients tested through Clalit Health Services (N0: n = 394, 49% CT-treated; N1mi/N1: n = 140, 62% CT-treated). The CT-treated and untreated groups were imbalanced (more high-risk clinicopathologic characteristics in CT-treated patients). With median follow-up of 8 years, Kaplan–Meier estimates for overall survival (OS), distant recurrence-free survival (DRFS), and BC-specific mortality (BCSM) were not significantly different between CT-treated and untreated N0 patients. Seven-year rates (95% CI) in CT-treated vs untreated: OS, 97.9% (94.4–99.2%) vs 97.9% (94.6–99.2%); DRFS, 91.5% (86.6–94.7%) vs 91.2% (86.0–94.6%); BCSM, 0.5% (0.1–3.7%) vs 1.6% (0.5–4.7%). For N1mi/N1 patients, OS/DRFS did not differ significantly between treatment groups; whereas BCSM did (1.3% [0.2–8.6%] vs 6.2% [2.0–17.7%] for CT-treated and untreated patients, respectively, p = 0.024).

show abstract

Ethnicity, recurrence score distribution, and clinical outcomes in ER + HER2‐negative breast cancer patients in Israel: A registry analysis

Cited by 2 publications

References 6 publications

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study

Contact Info

Product

Resources

About